A new method for producing urinary bladder hyperactivity using a non-invasive transient intravesical infusion of acetic acid in conscious rats.

INTRODUCTION Animal models that closely resemble the pathophysiology of human overactive bladder are important for evaluating novel therapeutics to treat the disorder. We established a non-invasive hyperactive bladder model that is sensitive to anti-muscarinic drugs and without bladder inflammation. METHODS Acetic acid solution was infused into the bladder for 5 min via the urethral orifice without any surgical procedures under isoflurane anaesthesia. After washing the bladder with saline, voiding frequency (VF) and total urine volume were determined for 9 h under conscious conditions. RESULTS Infusion of a 0.5% acetic acid solution caused a significant increase in VF, without influencing total urine volume or inducing significant histopathological inflammatory alterations in the bladder urothelium. Oral administration of oxybutynin (3 and 10 mg/kg) significantly ameliorated increases in VF induced by 0.5% acetic acid. Infusion of 0.75% acetic acid induced intensive urinary inflammation and a decrease in total urine volume as well as an increase in VF. Oral treatment with oxybutynin (10 mg/kg) did not significantly improve the increased VF due to 0.75% acetic acid. Acetic acid (0.5%) infusion evoked bladder hyper-responsiveness whether applied at night or during the day. However, VF was increased more by the nighttime application of acetic acid, while there were no significant differences in basal levels of VF between daytime and nighttime. DISCUSSION In this study, the non-invasive rat urinary hyperactive bladder model indicated minimizes the secondary effects of experimental procedures such as surgical operations and anesthesia on bladder function and is sensitive to oxybutynin. Thus, the model may be useful for investigating novel therapeutics for OAB treatment.

[1]  G. McMurray,et al.  Animal models in urological disease and sexual dysfunction , 2006, British journal of pharmacology.

[2]  Felix Franks,et al.  In-Vitro Characterization of mCerulean3_mRuby3 as a Novel FRET Pair with Favorable Bleed-Through Characteristics , 2019, Biosensors.

[3]  C. Fowler Bladder afferents and their role in the overactive bladder. , 2002, Urology.

[4]  A. Brading A myogenic basis for the overactive bladder. , 1997, Urology.

[5]  S. Macdiarmid,et al.  Diagnosis of interstitial cystitis/ painful bladder syndrome in patients with overactive bladder symptoms. , 2007, Reviews in urology.

[6]  S L Stanton,et al.  The standardisation of terminology of lower urinary tract function , 1989, World Journal of Urology.

[7]  D. Mishell,et al.  Increased prevalence of interstitial cystitis in women with detrusor overactivity refractory to anticholinergic therapy. , 2005, Urology.

[8]  T. Shike,et al.  Animal models. , 2001, Contributions to nephrology.

[9]  A. Wein Pharmacological agents for the treatment of urinary incontinence due to overactive bladder , 2001, Expert opinion on investigational drugs.

[10]  Giorgio Sironi,et al.  Urodynamic effects of oxybutynin and tolterodine in conscious and anesthetized rats under different cystometrographic conditions , 2005, BMC pharmacology.

[11]  A. Wein,et al.  Overactive bladder: a better understanding of pathophysiology, diagnosis and management. , 2006, The Journal of urology.

[12]  K. Andersson Mechanisms of Disease: central nervous system involvement in overactive bladder syndrome , 2004, Nature Clinical Practice Urology.

[13]  M. Kakiuchi,et al.  Effects of various drugs on bladder function in conscious rats. , 1989, Japanese journal of pharmacology.

[14]  M. Fall,et al.  The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. , 2002, American journal of obstetrics and gynecology.

[15]  S. Zderic,et al.  Impact of state of arousal and stress neuropeptides on urodynamic function in freely moving rats. , 2006, American journal of physiology. Regulatory, integrative and comparative physiology.

[16]  A. Kawauchi,et al.  Classification Based on Overnight Simultaneous Monitoring by Electroencephalography and Cystometry , 1998, European Urology.

[17]  W. C. Groat,et al.  Effect of intravesical nitric oxide therapy on cyclophosphamide-induced cystitis. , 1999, The Journal of urology.

[18]  D. Giglio,et al.  Altered muscarinic receptor subtype expression and functional responses in cyclophosphamide induced cystitis in rats , 2005, Autonomic Neuroscience.

[19]  L. Eriksson,et al.  In vitro characterization of parasympathetic and sympathetic responses in cyclophosphamide-induced cystitis in the rat. , 2007, Basic & clinical pharmacology & toxicology.